EP2 Subtype of PGE2 Receptor: Potential Drug Target for PGE2-Related Diseases

Target Name: PTGER2

NCBI ID: G5732

PTGER2

EP2 Subtype of PGE2 Receptor: Potential Drug Target for PGE2-Related Diseases

Prostaglandin E2 (PGE2) is a potent signaling molecule that plays a crucial role in various physiological processes in the body. It is a potent vasoactive agent that regulates blood flow, and its levels are regulated by the body's natural inflammatory response. However, an imbalance in PGE2 signaling has been linked to the development of various diseases, including cardiovascular disease, cancer, and neurological disorders.

The Prostaglandin E2 receptor (PGER2) is a subtype of the PGE2 receptor that is primarily expressed in the endothelial cells of the body. It is involved in the regulation of blood vessel diameter, and has been shown to play a role in the development of cardiovascular disease.

Research has shown that an imbalance in PGE2 signaling can lead to the formation of aggregates of platelets, which can cause blood clots and the development of cardiovascular disease. Additionally, high levels of PGE2 have been linked to the development of cancer, and may also contribute to the development of neurodegenerative diseases.

Despite the potential for PGE2 to contribute to a range of diseases, research into its role in the development and progression of these conditions has been limited. The development of new treatments for PGE2-related diseases remains a major goal in the field of pharmacology.

One potential drug target for PGE2-related diseases is the EP2 subtype of the PGE2 receptor. The EP2 subtype is a G protein-coupled receptor (GPCR) that is involved in the regulation of inflammation, immune response, and pain perception.

Research has shown that the EP2 subtype of the PGE2 receptor is involved in the regulation of pain perception and that it may play a role in the development of chronic pain. Additionally, the EP2 subtype has been shown to be involved in the regulation of inflammation and has been linked to the development of inflammatory diseases.

Despite the potential for the EP2 subtype of the PGE2 receptor to be a drug target, research into its function in these diseases remains limited. The development of new treatments for PGE2-related diseases remains a major goal in the field of pharmacology.

In conclusion, the Prostaglandin E2 receptor (PGER2) is a crucial molecule that plays a role in various physiological processes in the body. The development of new treatments for PGE2-related diseases remains a major goal in the field of pharmacology. The EP2 subtype of the PGE2 receptor is a potential drug target for PGE2-related diseases, and further research is needed to understand its function in these conditions.

Protein Name: Prostaglandin E Receptor 2

Functions: Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the relaxing effect of this receptor on smooth muscle

The "PTGER2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTGER2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets